Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders for Galectin Therapeutics Inc., held on December 7, 2023. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market under the symbol GALT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders approved three primary matters at the annual meeting:
- Election of Directors: All 11 nominated directors were elected. Votes ranged from approximately 24.8 million to 25.6 million "For" votes, with broker non-votes totaling 18,910,166 for each director.
- Ratification of Auditors: Stockholders ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2023. The vote was 44,481,830 For, 252,254 Against, and 187,704 Abstain.
- Equity Plan Amendment: Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance. The vote was 23,901,293 For, 1,923,578 Against, and 186,751 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Cherry Bekaert LLP is the appointed auditor for the 2023 fiscal year.
- Verification of the increased share reserve (3,000,000 additional shares) under the 2019 Omnibus Equity Incentive Plan and its potential dilution impact.
- Review of the full slate of elected directors to ensure alignment with the company's strategic direction.